Introduction {#sec1_1}
============

Atherosclerotic diseases are commonly found in patients with type 2 diabetes mellitus. It is well-known that some traditional risk factors for atherosclerosis, such as obesity, hypertension and dyslipidemia, are frequently complicated by type 2 diabetes mellitus. Chronic kidney disease (CKD), which is defined by a reduced glomerular filtration rate (GFR) and/or proteinuria, also causes atherosclerotic diseases \[[@B1],[@B2]\]. Anemia and hyperuricemia, which are common in CKD patients \[[@B3],[@B4]\], are also risk factors for diabetic macroangiopathies in patients with type 2 diabetes complicated by CKD \[[@B5],[@B6]\]. A greater level of an intima-media thickening, a surrogate marker for atherosclerosis \[[@B7]\], and a high incidence of diabetic macroangiopathies are found in patients with later stages of diabetic nephropathy \[[@B8]\]. Therefore, an accumulation of the risk factors for cardiovascular events might be present in patients with diabetes mellitus and CKD.

In the present study, the prevalence of risk factors for atherosclerosis among type 2 diabetic patients with different stages of CKD was cross-sectionally investigated. The results highlight the importance of ranking the risk factors for atherosclerosis among type 2 diabetic patients with CKD.

Patients and Methods {#sec1_2}
====================

A total of 2,107 patients diagnosed with type 2 diabetes mellitus who underwent consecutive evaluations, including urinalysis and measurements of the serum creatinine levels, at the Department of Diabetes, Metabolism and Kidney Disease of the Edogawa Hospital, Tokyo, Japan between April 2008 and March 2011, were recruited for this study.

Obese individuals were defined as those with a BMI ≥25. Hypertension was defined as a systolic blood pressure ≥140 mm Hg and/or a diastolic blood pressure ≥90 mm Hg. Patients currently using antihypertensive medications were also classified as positive for hypertension.

Hypercholesterolemia was defined as either a serum concentration of total cholesterol ≥5.69 mmol/l, an LDL cholesterol level ≥3.62 mmol/l, or the current use of lipid-lowering agents. Hypo-HDL-cholesterolemia was defined by serum HDL cholesterol concentrations \<1.03 mmol/l. Hyperuricemia was defined either as a serum uric acid level \>416 μmol/l or the use of allopurinol according to the guidelines proposed by the Japanese Society of Gout and Nucleic Acid Metabolism \[[@B9]\]. Anemia was defined as a hemoglobin level \<135 g/l in males and \<120 g/l in females according to the guidelines of the European Renal Association -- European Dialysis and Transplantation Association \[[@B10]\] and the National Kidney Foundation \[[@B11]\].

The estimated GFR (eGFR) was calculated using the formula reported by Matsuo et al. \[[@B12]\]. This equation originated from the MDRD study group \[[@B13]\] and was adapted for Japanese individuals; it is recommended by the Japanese Society of Nephrology: eGFR (ml/min/ 1.73 m^2^) = 194 × Scr^−1.094^ × age^−0.287^ × 0.739 (if female). The CKD stage was classified according to the levels of the eGFR and the urinary albumin to creatinine rate based on the new classification of CKD proposed by the Kidney Disease: Improving Global Outcomes (KDIGO) in 2011 \[[@B14]\].

Ethics Statement {#sec2_1}
----------------

This study was conducted according to the principles expressed in the Declaration of Helsinki. The Ethics Committees of the Edogawa Hospital approved the protocol of this study and waived the need for written informed consent because this cross-sectional study analyzed anonymized data stored in the hospital database.

Statistical Methods {#sec2_2}
-------------------

All data are shown as means ± SD. The χ^2^ test was used to determine the differences in the prevalence of the risk factors among the subjects with different stages of GFR. An analysis of variance (ANOVA) was used to compare the number of risk factors and the HbA1c levels among the patients with different stages of GFR. Differences of p \< 0.05 (two-tailed) were considered to be statistically significant. The statistical software package JMP, version 8.0 (SAS Institute, Cary, N.C., USA), was used for all analyses.

Results {#sec1_3}
=======

Table [1](#T1){ref-type="table"} shows the clinical characteristics and laboratory parameters of the patients. The mean patient age was 63 ± 13 years, and 49% of the patients were ≥65 years. Sixty-two percent of the patients were male. The percentages of subjects with a current history of smoking, obesity, hypertension, hypercholesterolemia, hypo-HDL-cholesterolemia, hyperuricemia and anemia were 35, 44, 70, 61, 13, 21 and 26%, respectively. The prevalence of diabetic micro- and macroangiopathies was significantly greater in the patients with later stages of GFR (table [2](#T2){ref-type="table"}).

The prevalence of each risk factor for atherosclerosis is shown in figure [1](#F1){ref-type="fig"}. The prevalence of age ≥65 years, male gender, albuminuria (stages A2 and A3), hypertension, hypo-HDL-cholesterolemia, hyperuricemia and anemia was greater in the patients with later stages of GFR, whereas the prevalence of hypercholesterolemia and obesity did not differ between stages. The prevalence of a current history of smoking was lower in the patients with later stages of GFR. The cumulative numbers of risk factors for atherosclerosis were higher in the patients with later stages of GFR (3.1 ± 1.4, 3.6 ± 1.5, 4.1 ± 1.4, 5.2 ± 1.5, 6.1 ± 1.3 and 6.8 ± 1.3 in G1, G2, G3a, G3b, G4 and G5, respectively) when age ≥65 years, male gender, albuminuria, hypertension, hyperuricemia, anemia, hypo-HDL-cholesterolemia, hypercholesterolemia, obesity and a current history of smoking were selected as the risk factors (fig. [2](#F2){ref-type="fig"}).

The levels of HbA1c gradually decreased with the progression of GFR stages (10.0 ± 2.7, 8.9 ± 2.3, 8.2 ± 2.0, 7.9 ± 1.9, 7.7 ± 1.8 and 7.4 ± 1.6% in G1, G2, G3a, G3b, G4 and G5, respectively, p \< 0.001).

Discussion {#sec1_4}
==========

This study showed that risk factors for atherosclerosis, a condition that should be treated intensively in patients with type 2 diabetes mellitus and/or CKD, increased in patients with later stages of GFR and that the prevalence of risk factors differs between GFR stages. It has been established that aging, male gender, obesity, hypertension, hypercholesterolemia, hypo-HDL-cholesterolemia and a history of smoking are important risk factors for the development of cardiovascular events. It has also recently been recognized that albuminuria, anemia and hyperuricemia are associated with atherosclerotic diseases. In the present study, the prevalence of many risk factors was higher in type 2 diabetic patients with later stages of GFR. We have previously reported that micro- and macroangiopathies occur more frequently in type 2 diabetic patients with GFR stages 3-5 than in those with GFR stage 1 or 2, even if albuminuria is not found \[[@B15]\]. The higher prevalence of micro- and macroangiopathies might be associated with the accumulation of other risk factors in the progressive stages of GFR. In the present study, overt proteinuria (10 vs. 4%), hypertension (64% in males and 50% in females vs. 60% in males and 44.6% in females), hypercholesterolemia (48 vs. 22.3% in males and 69 vs.17.7% in females), and obesity (44 vs. 31.4% in males and 49 vs. 22.2% in females) were more frequently found even in patients with GFR stage 1 and 2 compared with the Japanese adult population according to recent statistics from the Ministry of Health, Labour and Welfare \[[@B16],[@B17]\]. Furthermore, twice the number of risk factors was observed in type 2 diabetic patients with GFR stage 4 or later. We must pay attention to the increases in hyperuricemia and anemia in the progressive stages of GFR; however, the prevalence of these risk factors in the earlier stages of GFR does not differ from that seen in the general population \[[@B5],[@B6]\].

Tanaka et al. \[[@B18]\] have recently reported that the prevalence of macrovascular disease was found to be increased from the GFR stage 3 in 1,493 Japanese diabetic CKD patients. In this study, the prevalence of older age, male gender, hypertension, a past (but no current) history of smoking and hyperuricemia increased with the progression of GFR stages, although the prevalence of hyperlipidemia did not change. The levels of HbA1c and hemoglobin decreased in later stages of GFR, similar to the results of our study. Nakagawa et al. \[[@B19]\] showed that the prevalence of dyslipidemia and hypertension increased with the progression of GFR stages in the general population (n = 647), including patients with type 2 diabetes mellitus. The reason for the difference in the prevalence of dyslipidemia observed between the study conducted by Nakagawa et al. \[[@B19]\], the study conducted by Tanaka et al. \[[@B18]\] and our study is unclear; however, relatively small numbers of subjects with GFR stages 4 and 5 (n = 12 and 5, respectively) were included in the study conducted by Nakagawa et al. \[[@B19]\], which might have resulted in a high frequency of dyslipidemia and a prevalence of obesity and smoking in the later stages of GFR. Iseki et al. \[[@B20]\] have demonstrated that the prevalence of hypertension and proteinuria and the frequencies of obesity and smoking are decreased in the progressive stages of GFR in the general population. However, the relationship between dyslipidemia and the GFR stage was not described.

Recently, Dzau et al. \[[@B21]\] have proposed the concept of the cardiorenal continuum. Various mechanisms are assumed to be present in these cardiovascular and kidney diseases, such as reduced NO production, activation of the tissue renin-angiotensin system and inflammation \[[@B22]\]. The association between these mechanisms is considered to be simply expressed as an increased number of risk factors for atherosclerosis in the clinical assessment of type 2 diabetic patients with CKD.

The present study has limitations that should be kept in mind when considering the results. First, our study used a cross-sectional design and was therefore unable to show any causal effects between the GFR stage and the prevalence of the risk factors for atherosclerosis. This study only demonstrated an association between the GFR stage and the prevalence of risk factors in a large number of subjects. Second, we did not examine other risk factors, such as family/previous history of vascular events or serum triglyceride concentrations. Sone et al. \[[@B23]\] showed that the serum triglyceride level is an important risk factor for coronary heart disease using a longstanding observational study of a larger number of Japanese patients with type 2 diabetes mellitus.

In conclusion, it is noteworthy that risk factors for atherosclerosis differ between the stages of GFR. In this study, the total number for atherosclerosis in patients with type 2 diabetes mellitus increased with the progression of renal dysfunction. It is important to pay attention to hyperuricemia and anemia, which are newly recognized risk factors for atherosclerosis, in addition to hypertension, albuminuria and hypo-HDL-cholesterolemia. A study investigating the effects of comprehensive interventions for these risk factors is expected in the future.
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![The prevalence of risk factors for atherosclerosis among type 2 diabetic patients with different stages of GFR. Albuminuria includes stages A2 and A3. The χ^2^ test was used to determine the differences in the prevalence of the risk factors among the subjects with different stages of GFR.](nne-0003-0066-g01){#F1}

![The cumulative number of risk factors for atherosclerosis among type 2 diabetic patients with different stages of GFR. Age ≥65 years, male gender, albuminuria, hypertension, hyperuricemia, anemia, hypo-HDL-cholesterolemia, hypercholesterolemia, obesity and a current history of smoking were selected as the risk factors. ANOVA was used to compare the numbers of risk factors between the GFR stages.](nne-0003-0066-g02){#F2}

###### 

Clinical characteristics of the patients

                                                             Mean±SD          Evaluated patients, n
  ---------------------------------------------------------- ---------------- -----------------------
  Age, years                                                 63±13            2,107
  Males, %                                                   62               2,107
  Duration of diabetes mellitus, years                       9±10             1,794
  Current smokers, %                                         35               1,647
  Treatment for diabetes mellitus                                             
  Diet only/OHA/insulin, %                                   17/56/27         2,107
  Body mass index                                            24.9±4.3         2,078
  Obesity, %                                                 44               2,078
  HbA1c, %                                                   8.4±2.2          1,964
  Hypertension, %                                            70               2,107
  Systolic blood pressure, mm Hg                             138±21           2,107
  Diastolic blood pressure, mm Hg                            80±14            2,107
  Hypercholesterolemia, %                                    61               2,102
  Total cholesterol, mmol/l                                  5.2±1.2          1,800
  LDL cholesterol, mmol/l                                    3.2±1.0          1,427
  Hypo-HDL-cholesterolemia, %                                13               1,598
  HDL cholesterol, mmol/1                                    1.5±0.4          1,598
  Serum creatinine, μmol/l                                   86±51            2,107
  Estimated GFR, ml/min/1.73 m^2^                            55±20            2,107
  GFR stage, % G1/G2/G3a/G3b/G4/G5                           5/32/34/20/7/2   2,107
  Albuminuria stage, % A1/A2/A3                              53/24/23         2,027
  Hyperuricemia, %                                           21               2,096
  Serum uric acid, μmol/l                                    307±89           2,096
  Anemia, %                                                  26               2,101
  Hemoglobin, g/dl                                           135±17           2,101
  Diabetic retinopathy[^1^](#T1F1){ref-type="table-fn"}, %   40               1,588
  Diabetic neuropathy, %                                     68               1,575
  Cerebrovascular disease, %                                 13               2,106
  Coronary heart disease, %                                  19               2,105
  Peripheral arterial disease, %                             5                2,107

OHA = Oral hypoglycemic agents.

Diabetic retinopathy includes simple, preproliferative and proliferative retinopathies.

###### 

Prevalence of diabetic micro- and macroangiopathies between the GFR stages

  GFR stage                                      Gl (105)   G2 (668)   G3a (716)   G3b (411)   G4 (157)   G5 (50)   p
  ---------------------------------------------- ---------- ---------- ----------- ----------- ---------- --------- ---------
  Retinopathy[^1^](#T2F1){ref-type="table-fn"}   36         34         33          45          70         85        \<0.001
  Nephropathy[^2^](#T2F2){ref-type="table-fn"}   46         35         41          53          93         100       \<0.001
  Neuropathy                                     64         60         66          75          84         87        \<0.001
  Cerebrovascular disease                        3          9          14          18          17         26        \<0.001
  Coronary heart disease                         9          10         18          29          34         28        \<0.001
  Peripheral artery disease                      5          2          5           8           9          10        \<0.001

Values are given as percentages (values in parentheses represent patient numbers).

Diabetic retinopathy includes simple, preproliferative and proliferative retinopathies.

Diabetic nephropathy includes stages A2 and A3.
